PASG — Passage Bio Inc
NASDAQ · Healthcare · Biotechnology
$4.41
-$0.03 (-0.68%)
Passage Bio Inc (PASG) is a biotechnology company listed on NASDAQ. It is led by William Chou M.D., based in One Commerce Square, Philadelphia, PA, United States, 19103, with about 60 employees. Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Net income was -$7.7M. PASG currently screens at market cap $25.2M.
Use this PASG page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PASG quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PASG SEC filings page. Lician reads the product cache first so this HTML stays unique to Passage Bio Inc even when a live quote feed is slow.
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
PASG Key Statistics
Market Cap
$25.23M
Volume
1,561
Previous Close
$4.83
Day Range
$4.54 – $4.79
EPS
-$1.07
Revenue
$0.00
Net Income
-$64.77M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
60
PASG Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$64.77M | -$102.06M | -$136.13M | -$185.39M |
| EPS (Diluted) | -$1.07 | -$1.86 | -$2.50 | -$3.48 |
Total Assets
$102.41M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$37.57M
Operating Cash Flow
-$47.96M
Free Cash Flow
$0.00
Passage Bio Inc Company Information
- President, CEO & Director
- William Chou M.D.
- Headquarters
- One Commerce Square, Philadelphia, PA, United States, 19103
- Website
- www.passagebio.com
- Phone
- (267) 866-0311
- IPO / Founded
- 2020-02-28
- Sector
- Healthcare
- Industry
- Biotechnology